Fluvastatin therapy could not decrease progression of paroxysmal atrial fibrillation in non-valvular disease patients

• Published in: Anatolian journal of cardiology 2017-08, Vol.18 (2), p.103-107
• Main Authors: Tan, Qiang, Zhang, Shuangyue, Zou, Xiaoyi, Zhao, Jun, Hao, Jia, Sun, Qian
• Format: Article
• Language: English
• Subjects: Aged; Atrial Fibrillation - drug therapy; Atrial Fibrillation - physiopathology; Cardiac arrhythmia; Case-Control Studies; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Fluvastatin - administration & dosage; Fluvastatin - therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Male; Original Investigation; Prospective Studies; Treatment Outcome
• ISSN: 2149-2263; 2149-2271
• DOI: 10.14744/AnatolJCardiol.2017.7664

This study aimed to evaluate whether fluvastatin therapy could decrease the probability of atrial fibrillation (AF) progression from paroxysmal AF to permanent AF and decrease the recurrence frequency of AF. Analyses were performed using two-tailed Student's t test or Mann-Whitney U tests. Categorical variables were compared with the χ2 statistics or Fisher's exact test. Patients with paroxysmal AF were randomized case-control, prospective into either the fluvastatin group (n=61) or control group (n=57). Patients were followed up for 24 months. The primary endpoint event was paroxysmal AF that progressed to permanent AF. Secondary endpoints were AF recurrence, cardiac dysfunction, stroke, or death. There were no differences in AF progression (fluvastatin group, 8.19% vs. control group, 12.51%; p>0.05) and stroke (fluvastatin group. 6.55% vs. 8.77%; p>0.05). Patients in the fluvastatin group had a lower rate of AF recurrence (fluvastatin group, 24.59% vs. control group, 49.12%; p